The aim of this phase II multicentric study was to evaluate the efficacy and toxicity of neo-adjuvant chemotherapy with weekly topotecan and cisplatin in locally-advanced squamous cervical cancer.From November 2008 to January 2011, 92 patients met the inclusion criteria and were enrolled. Eligibility criteria were: squamous or adenosquamous cervical cancer; clinical stages IB2, IIA, IIB; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)≤ 2; neutrophils ≥1500/μL; platelets ≥100,000/μL, normal renal and liver function. Treatment consisted of six courses of weekly topotecan (2mg/m(2)) and cisplatin (40 mg/m(2)). All responsive and stable patients were submitted to radical surgery, while progressed cases underwent definitive radiotherapy±chemotherapy. Primary end-point was evaluation of efficacy and toxicity. All patients are evaluable for toxicity and efficacy.Ninety-six percent of patients completed the six planned courses of chemotherapy, and 95\% of courses were administered at a full dose and without interruption or delay. Mean age was 49 years (35-64 years). FIGO Stage distribution was 30 IB2, 13 IIA and 49 IIB. Treatment was well tolerated and no death occurred. G3-G4 haematological toxicity was observed in 28\% of patients (5\% out of cycles). Support therapies (blood transfusions and/or erythropoietin and/or Granocyte-Colony Stimulating Factor) were given to 24\% of patients. Clinical response rate was 77\%. The nine progressed cases were irradiated, while the remaining 83 patients were submitted to radical surgery. An overall pathologic response was observed in 67\% of patients, with an optimal response rate of 32\% and a disease downstage in 57\% of patients. Nodal metastases occurred in 36\% of patients. Adjuvant therapy (radiotherapy and or chemotherapy) was prescribed in 55\% of patients, because of lymph node metastases, parametrial or vaginal involvement or cut-through margins. Median follow-up was 18 months: 76\% of patients are alive and free from recurrence, 24\% of patients relapsed and 13\% died.Weekly topotecan and cisplatin showed an acceptable toxicity profile; the promising response rate warrants further investigation.

Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.

GHEZZI, FABIO;
2013-01-01

Abstract

The aim of this phase II multicentric study was to evaluate the efficacy and toxicity of neo-adjuvant chemotherapy with weekly topotecan and cisplatin in locally-advanced squamous cervical cancer.From November 2008 to January 2011, 92 patients met the inclusion criteria and were enrolled. Eligibility criteria were: squamous or adenosquamous cervical cancer; clinical stages IB2, IIA, IIB; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)≤ 2; neutrophils ≥1500/μL; platelets ≥100,000/μL, normal renal and liver function. Treatment consisted of six courses of weekly topotecan (2mg/m(2)) and cisplatin (40 mg/m(2)). All responsive and stable patients were submitted to radical surgery, while progressed cases underwent definitive radiotherapy±chemotherapy. Primary end-point was evaluation of efficacy and toxicity. All patients are evaluable for toxicity and efficacy.Ninety-six percent of patients completed the six planned courses of chemotherapy, and 95\% of courses were administered at a full dose and without interruption or delay. Mean age was 49 years (35-64 years). FIGO Stage distribution was 30 IB2, 13 IIA and 49 IIB. Treatment was well tolerated and no death occurred. G3-G4 haematological toxicity was observed in 28\% of patients (5\% out of cycles). Support therapies (blood transfusions and/or erythropoietin and/or Granocyte-Colony Stimulating Factor) were given to 24\% of patients. Clinical response rate was 77\%. The nine progressed cases were irradiated, while the remaining 83 patients were submitted to radical surgery. An overall pathologic response was observed in 67\% of patients, with an optimal response rate of 32\% and a disease downstage in 57\% of patients. Nodal metastases occurred in 36\% of patients. Adjuvant therapy (radiotherapy and or chemotherapy) was prescribed in 55\% of patients, because of lymph node metastases, parametrial or vaginal involvement or cut-through margins. Median follow-up was 18 months: 76\% of patients are alive and free from recurrence, 24\% of patients relapsed and 13\% died.Weekly topotecan and cisplatin showed an acceptable toxicity profile; the promising response rate warrants further investigation.
2013
http://dx.doi.org/10.1016/j.ejca.2012.10.008
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage/adverse effects, Carcinoma; Adenosquamous; drug therapy/mortality/pathology, Carcinoma; Squamous Cell; drug therapy/mortality/pathology, Cisplatin; administration /&/ dosage/adverse effects, Disease Progression, Drug Administration Schedule, Female, Humans, Middle Aged, Neoadjuvant Therapy, Topotecan; administration /&/ dosage/adverse effects, Treatment Outcome, Uterine Cervical Neoplasms; drug therapy/mortality/pathology, Young Adult
F., Zanaboni; B., Grijuela; S., Giudici; G., Cormio; L., Babilonti; Ghezzi, Fabio; G., Giorda; G., Scambia; M., Franchi; M., Lorusso; A., Ditto; D., L...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/1879157
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 21
social impact